Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) COO Pad Chivukula sold 12,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Arcturus Therapeutics Trading Down 1.6 %

ARCT traded down $0.34 during trading hours on Wednesday, hitting $20.63. The company's stock had a trading volume of 256,530 shares, compared to its average volume of 478,999. The company has a 50-day simple moving average of $21.02 and a 200 day simple moving average of $25.57. The firm has a market capitalization of $555.61 million, a PE ratio of -5.36 and a beta of 2.61. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $17.52 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period last year, the company earned ($1.98) earnings per share. Research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new stake in Arcturus Therapeutics during the first quarter worth approximately $40,000. nVerses Capital LLC acquired a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at $42,000. Quest Partners LLC raised its stake in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock worth $90,000 after buying an additional 3,579 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics in the 2nd quarter worth $142,000. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock valued at $152,000 after buying an additional 428 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ARCT. Leerink Partnrs raised shares of Arcturus Therapeutics to a "strong-buy" rating in a report on Monday, August 12th. Leerink Partners started coverage on Arcturus Therapeutics in a report on Monday, August 12th. They issued an "outperform" rating and a $70.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus target price of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.